This is a multicenter, randomized, double-masked, controlled, phase III study of repeated use of C31G vaginal gel compared to Conceptrol® Vaginal Gel as the primary method of contraception over six months (183 days) and at least six cycles of use. In addition, there is an opportunity for subjects to continue with study treatment for up to twelve months (365 days) and twelve cycles of treatment upon completion of the first six months of treatment.

NCT00274261

Conditions

1. Pregnancy

Interventions

1. Drug: C31G
2. Drug: nonoxynol-9 (N-9)

A Phase II/III Multicenter, Randomized, Double-masked, Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®. --- C31G ---

Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol® This is a multicenter, randomized, double-masked, controlled, phase III study of repeated use of C31G vaginal gel compared to Conceptrol® Vaginal Gel as the primary method of contraception over six months (183 days) and at least six cycles of use. --- C31G ---

Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol® This is a multicenter, randomized, double-masked, controlled, phase III study of repeated use of C31G vaginal gel compared to Conceptrol® Vaginal Gel as the primary method of contraception over six months (183 days) and at least six cycles of use. --- C31G --- --- C31G ---

The Cumulative Probability of Typical-use 6 Month (183 Days) Pregnancy.. Number of pregnancies in women using C31G gel for 6 months (183 days) compared to women using Conceptrol gel for the same time frame.. Incidence of Adverse Events.. Evaluated by comparing the incidence of Adverse Events (AEs) among subjects using their assigned treatment for at least one day.. Inclusion Criteria: Potential subjects must: - Be healthy women, who are sexually active, at risk for pregnancy and desiring contraception. --- C31G ---

- Have previously participated in or completed this study or any other phase III study of C31G. --- C31G ---

C31G is an effective spermicide with in vitro activity equal to that of N-9 . --- C31G ---

C31G has been found to be a broad-spectrum antibacterial agent in vitro or in animals, active against both gram-positive and gram-negative organisms, including chlamydia, and a range of antibiotic resistant strains. --- C31G ---

Thus, the primary objective of the study is to determine the contraceptive efficacy of C31G vaginal gel compared to Conceptrol® Vaginal Gel. --- C31G ---

Additional evaluations include the incidence of urinary tract infections (UTI), bacterial vaginosis (BV) and yeast vaginitis following the use of C31G vaginal gel compared to Conceptrol® Vaginal Gel. --- C31G ---

Heterosexual contact is now the primary route of transmission for HIV worldwide. This study is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk.

NCT00129532

Conditions

1. HIV Infections

Interventions

1. Drug: 1.0% C31G SAVVY vaginal gel

MeSH:HIV Infections

This study is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk. --- C31G ---

This study is a phase 3 multi-center, fully-masked, randomized, placebo controlled trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk. --- C31G ---

Heterosexual contact is now the primary route of transmission for HIV worldwide. This study is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk.

NCT00130078

Conditions

1. HIV Infections

Interventions

1. Drug: 1.0% C31G SAVVY vaginal gel

MeSH:HIV Infections

This study is a phase 3 trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk. --- C31G ---

This study is a phase 3 multi-center, fully-masked, randomized, placebo controlled trial designed to determine the effectiveness and safety of the 1.0% C31G (SAVVY) vaginal gel for the prevention of male-to-female transmission of HIV among women at high risk. --- C31G ---

Aim: This study compared the effectiveness of three different mouthrinses (alcohol and non-alcohol chlorhexidine, alkyl dimethyl glycine / alkyl dimethyl amine oxide - C31G) in plaque control and early wound healing, postoperatively. Materials and Methods: In this, randomized, double-blind, controlled clinical trial 42 patients were allocated to three groups assigned to two weeks rinsing after periodontal surgery with C31G (group A), alcohol-free chlorhexidine 0.12% (group B) or alcohol-based chlorhexidine 0.12% (group C). At weeks 1 and 2, plaque and early wound healing indices were recorded. At day 14, total bacterial counts were estimated utilizing real - time qPCR. Statistics included linear and generalized linear mixed models.

NCT03119831

Conditions

1. Periodontitis
2. Wound Healing

Interventions

1. Drug: Alcohol-based Chlorhexidine Gluconate 0.12%
2. Drug: Alcohol-free Chlorhexidine Gluconate 0.12%
3. Drug: C31G

MeSH:Periodontitis Dental Plaque Wounds and Injuries

HPO:Periodontitis

Effectiveness of Three Different Mouthrinses in Dental Plaque Control and Early Wound Healing Aim: This study compared the effectiveness of three different mouthrinses (alcohol and non-alcohol chlorhexidine, alkyl dimethyl glycine / alkyl dimethyl amine oxide - C31G) in plaque control and early wound healing, postoperatively. --- C31G ---

Materials and Methods: In this, randomized, double-blind, controlled clinical trial 42 patients were allocated to three groups assigned to two weeks rinsing after periodontal surgery with C31G (group A), alcohol-free chlorhexidine 0.12% (group B) or alcohol-based chlorhexidine 0.12% (group C). --- C31G ---